Variability of Sulfotransferase 1A1 Activity in Humans: an Approach to Improve Predictive Drug Response - Part I: Analysis of Intraindividual Variation in Healthy Adults

Healthy Volunteers Clinical Trial

Official title:

Variability of Sulfotransferase 1A1 Activity in Humans: an Approach to Improve Predictive Drug Response - Part I: Analysis of Intraindividual Variation in Healthy Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03182595
• Other study ID #: HLUZ_001_2016
• Status: Completed
• Phase: Phase 1
• Start date: March 17, 2017
• Est. completion date: December 31, 2018

Study information

• Verified date: August 2021
• Source: Hospital da Luz, Portugal
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An open-label, single centre, nonrandomized clinical study in healthy volunteers, with intervention over a 13---week period. After written informed consent, subjects will undergo screening evaluations (Visit 1). One week after visit 1, subjects who meet the selection criteria will enter a run---in period of 8 weeks where participants will receive paracetamol 1g tablet and collect a blood sample at monthly intervals (visits 2, 3 and 4). A final visit for safety assessment will take place at week 13 (visit 5). Blood samples will be used to quantify P, PG e PS.

Description:

To be able to predict efficacy and adverse reactions involving compounds metabolized by sulfonation, the investigators need more information on SULTs. Studies of in vivo sulfonation in humans are lacking, although they are of key importance in assessing the functional consequences of individual variation. In our current study, the investigators will start by developing an HPLC method of quantifying SULT1A1 activity using paracetamol as probe substrate and studying intraindividual variation in healthy adults. Advantages of using paracetamol as a probe substrate for in vivo phenotyping of SULT1A1 include: wide safety margin for in vivo use, easy and ready administration of the drug, significant metabolism by the enzyme of interest, short half---life, linear pharmacokinetics over a wide concentration range and a limited number of metabolites, quantifiable in plasma.15,24 In a subsequent study, the investigators plan to study interindividual variation in a larger sample, including subjects with chronic disease and on medication.The investigators expect to provide a valuable new tool to explore the clinical significance of variation of SULT1A1 activity, the most important SULT on drug metabolism.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: December 31, 2018
• Est. primary completion date: January 31, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Healthy males and females, over 18 years of age,
• Informed of the nature of the study and giving written informed consent,
• Report no significant diseases during screening,
• Have normal CBC, renal function and liver enzymology,
• Have no contraindication for paracetamol,
• Be on no regular medical treatment, except for contraceptives,
• Be able to communicate effectively with study personnel.

Exclusion Criteria:

• Hypersensitivity or idiosyncratic reaction to paracetamol,
• Intake of any medication, except for contraceptives, within 14 days before start of the study,
• Pregnancy or breastfeeding,
• BMI <18 kg/m2,
• Participation in a clinical study of any investigational product 1 month prior to visit 1 or during the study.

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• Paracetamol
Volunteers will be screened at visit 1, and if they meet the inclusion/exclusion criteria they will receive the intervention at visit 2. At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have a blood sample collected 2 hours after administration; these procedures will be repeated on 2 more occasions (visits 3 and 4). The subjects will come for 5 visits during the study. Visit 1 and 2 must occur within 7 days of each other, visits 2, 3 and 4 will be four weeks (± 3 days) apart and visit 5 scheduled four weeks (± 3 days) after visit 4.

Locations

Country	Name	City	State
Portugal	Hospital da Luz	Lisboa

Sponsors (2)

Lead Sponsor	Collaborator
Hospital da Luz, Portugal	Universidade Nova de Lisboa

Country where clinical trial is conducted

Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	- Coefficient of variation of paracetamol sulfonation index (PSI), a ratio between the measured plasma concentrations of paracetamol sulfate (PS) and PS+ paracetamol glucoronide (PG) + paracetamol (P)		9 months
Secondary	Reproductibility, sensitivity and accuracy of the HPLC method (human samples will be used to validate the method);		9 months
Secondary	Relationships between PSI and subject characteristics (gender, age, genotype, smoking status, caffeine consumption, alcohol consumption, oral contraceptive use);		9 months
Secondary	Relationship between SULTA1 expression and predose and postdose metabolic profiles;		9 months
Secondary	Association between SULT1A1 genotype and SULT1A1 expression (optional);		9 months
Secondary	Association between PSI and SULT1A1 genotype (optional).		9 months